We are thrilled to be working with AlzeCure Pharma on their pilot study with Painless ACD440 in peripheral neuropathic pain, where we will implement a new digital element for decentralized activities. This will create a smooth and flexible process for patient recruitment and will help with the pre-screening, eConsent, and remote visits via Viedoc Me while feeding in information to the eCRF.
In this picture, our team collaborates with Viedoc and the participating clinic to create a short information film for the patients. The video will be available through Viedoc during the eConsent process at the beginning of the study.
AlzeCure® is a Swedish pharmaceutical company that develops new innovative small molecule drug therapies for the treatment of severe diseases and conditions that affect the central nervous system, such as Alzheimer’s disease and pain – indications for which currently available treatment is very limited. The company is listed on Nasdaq First North Premier Growth Market and is developing several parallel drug candidates based on three research platforms: NeuroRestore®, Alzstatin® and Painless.
A strategic partnership with LINK Medical offers the expertise and guidance you need to accelerate your
time to market.
